Holen Sie sich die Stockscreener-App
2.77
3.36%
0.09
Handel nachbörslich:
2.78
0.010
+0.36%
Schlusskurs vom Vortag:
$2.68
Offen:
$2.64
24-Stunden-Volumen:
277.37K
Relative Volume:
0.71
Marktkapitalisierung:
$127.96M
Einnahmen:
$2.76M
Nettoeinkommen (Verlust:
$-49.12M
KGV:
-1.8467
EPS:
-1.5
Netto-Cashflow:
$-46.21M
1W Leistung:
-13.98%
1M Leistung:
-2.81%
6M Leistung:
-30.75%
1J Leistung:
-61.10%
1-Tages-Spanne:
$2.60
$2.94
1-Wochen-Bereich:
$2.60
$3.29
52-Wochen-Spanne:
$2.37
$8.8699
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
Firmenname
Orchestra Biomed Holdings Inc
Sektor
Branche
Telefon
646-343-9298
Adresse
150 UNION SQUARE DRIVE, NEW HOPE
Vergleichen Sie OBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
2.77 | 127.96M | 2.76M | -49.12M | -46.21M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-20 | Eingeleitet | BTIG Research | Buy |
| 2025-01-02 | Eingeleitet | Barclays | Overweight |
| 2024-08-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-25 | Eingeleitet | B. Riley Securities | Buy |
| 2024-01-19 | Eingeleitet | Jefferies | Buy |
| 2023-02-24 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-07 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Orchestra Biomed Holdings Inc Aktie (OBIO) Neueste Nachrichten
Orchestra BioMed Showcases AVIM Therapy as Purpose-Built - GlobeNewswire
Millennium Management LLC Makes New Investment in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
Citadel Advisors LLC Sells 7,836 Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
(OBIO) Trading Advice - news.stocktradersdaily.com
Orchestra Biomed Reports Increased Losses Amid Revenue Growth - TipRanks
B. Riley Cuts Price Target on Orchestra BioMed Holdings to $12 From $15, Keeps Buy Rating - marketscreener.com
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Stake Increased by Northern Trust Corp - Defense World
Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships - Seeking Alpha
Orchestra BioMed Reports Q1 2025 Financial Results and Advances Key Clinical Programs - MSN
How To Trade (OBIO) - news.stocktradersdaily.com
The Manufacturers Life Insurance Company Raises Position in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
FY2026 Earnings Estimate for OBIO Issued By Chardan Capital - Defense World
Orchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough Designation - MSN
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates - MSN
Chardan Capital Maintains Buy Rating on OBIO with $20 Price Targ - GuruFocus
Barclays PLC Boosts Holdings in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
Wells Fargo & Company MN Buys 3,992 Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
Orchestra BioMed HoldingsBreakthrough Device Designation Gives Speculative Optimism - Seeking Alpha
Chardan Capital Maintains Buy Rating on OBIO with $20 Price Target | OBIO Stock News - GuruFocus
Orchestra BioMed (OBIO) Surpasses Revenue Estimates with Strong Q1 Growth | OBIO Stock News - GuruFocus
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones - The Manila Times
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy and IDE Approval for Virtue SAB Trial - Nasdaq
Orchestra BioMed Reports First Quarter 2025 Financial - GlobeNewswire
4 No-Brainer Stocks to Buy Right Now - The Globe and Mail
(OBIO) On The My Stocks Page - news.stocktradersdaily.com
Orchestra BioMed receives FDA approval to initiate Virtue Trial - Med-Tech Insights
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Shares Sold by Price T Rowe Associates Inc. MD - The AM Reporter
RTW INVESTMENTS, LP Increases Stake in Orchestra BioMed Holdings Inc - GuruFocus
ORCHESTRA BIOMED Earnings Preview: Recent $OBIO Insider Trading, Hedge Fund Activity, and More - Nasdaq
Orchestra BioMed’s AVIM Therapy Global Intellectual - GlobeNewswire
Orchestra BioMed (OBIO) Expands Patent Portfolio for AVIM Therap - GuruFocus
Orchestra BioMed Expands Patent Portfolio with 10 New Patents for Hypertension Treatment, Totaling 120 Global Patents - Nasdaq
Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure - GlobeNewswire
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - MSN
BlackRock, Inc. Reduces Stake in Orchestra BioMed Holdings Inc. - GuruFocus
Orchestra BioMed (NASDAQ:OBIO) Price Target Lowered to $12.00 at Barclays - Defense World
Orchestra BioMed Holdings (OBIO) Target Price Adjustment by Barc - GuruFocus
Barclays Adjusts Price Target for Orchestra BioMed (OBIO) | OBIO Stock News - GuruFocus
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Shares Bought by JPMorgan Chase & Co. - Defense World
OBIO: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
How did Orchestra BioMed Holdings Inc (OBIO) fare last session? - uspostnews.com
Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment - MyChesCo
Orchestra Biomed sees $149,201 stock purchase by RTW Investments By Investing.com - Investing.com Australia
Orchestra BioMed Holdings Inc [OBIO] Records 200-Day SMA of $5.25 - knoxdaily.com
Orchestra BioMed to Present at Jefferies Global Healthcare Conference - MyChesCo
Finanzdaten der Orchestra Biomed Holdings Inc-Aktie (OBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):